• Company Type For Profit
AkaRx, Inc., a biopharmaceutical company, develops therapeutic treatments for unmet medical needs. Its product includes AKR-501, an orally-available small molecule for use in the treatment of thrombocytopenia. The company was founded in 2005 and is headquartered in Paramus, New Jersey.

Lists Featuring This Company

United States Biotechnology Companies (Top 10K)
9,982 Number of Organizations â€¢ $689.5B Total Funding Amount â€¢ 29,920 Number of Investors
East Coast Biopharma Companies
702 Number of Organizations â€¢ $38.6B Total Funding Amount â€¢ 1,758 Number of Investors
United States Therapeutics Companies (Top 10K)
9,666 Number of Organizations â€¢ $212.6B Total Funding Amount â€¢ 10,381 Number of Investors
Companies That Exited in 2010
5,715 Number of Organizations â€¢ $167.2B Total Funding Amount â€¢ 3,678 Number of Investors
AkaRx was acquired by Eisai for $255M on Jan 7, 2010.

Frequently Asked Questions

Where is AkaRx's headquarters? AkaRx is located in Paramus, New Jersey, United States.Who invested in AkaRx? AkaRx has 2 investors including Sutter Hill Ventures and InterWest Partners.How much funding has AkaRx raised to date? AkaRx has raised .When was the last funding round for AkaRx? AkaRx closed its last funding round on Jul 13, 2007 from a Venture - Series Unknown round.Who are AkaRx's competitors? Alternatives and possible competitors to AkaRx may include Anthos TherapeuticsAtterx Biotherapeutics, and Resolvyx Pharmaceuticals.